SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Few months ago, Solarwindow Technologies Inc (OTCMKTS:WNDW) made a 52-week low of 1.10 per share. At that time it used to trade under the symbol NENE. The people who went to buy the stock at those levels are quite happy with themselves. From thereon, the stock has almost doubled and is trading around $2 mark.

The volatility

Despite the fact that Solarwindow stock price doubled in last few months, the experts are not optimistic above the company. The past performance of the OTC stocks shows that the sharp spikes in the stock process are followed by scary drops. The problems deepen when the surge in stock prices is not supported by healthy volume, indicating it more of a artificially created hype.

The news

The movement of Solarwindow has become quite unpredictable these days. At the start of the month, the company released a positive press release following which the stock price surged in the right direction. Even, it tried to make a new 52-week high after the news. However, optimism faded away soon and with no warning the stock prices declined in red zone. There stock witnessed some wild swings.

The future ahead

Solarwindow Technologies Inc (OTCMKTS:WNDW) failed to make any gains from the new symbol. It didn’t support the performance for longer time. On March 12 the stock price ended in green but soon it also vanished away. The people who are invested for long-term are unaffected by the price volatilities as the company offers products in a growing market.

The performance

As per the last 10-Q, Solarwindow mentioned that the company has generated no revenue from its operations. Also, it doesn’t expect to generate revenue in the near term. The statement by the management of the company serves as a warning for people who are looking to invest in the company’s stock for short term.